Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F2,F3	Sep 5, 2017	J	1,308,234	$0.00	D	9,887,928	I	TCV VII, L.P.
Common Stock^F2,F5	Sep 5, 2017	J	679,396	$0.00	D	5,135,030	I	TCV VII (A), L.P.
Common Stock^F2,F7	Sep 5, 2017	J	12,370	$0.00	D	93,493	I	TCV Member Fund, L.P.
Common Stock^F2,F9	Sep 5, 2017	J	501,768	$0.00	A	501,768	I	Technology Crossover Management VII, L.P.
Common Stock^F2,F9	Sep 5, 2017	J	497,779	$0.00	D	3,989	I	Technology Crossover Management VII, L.P.
Common Stock^F2,F12	Sep 5, 2017	J	46,525	$0.00	A	46,525	I	Hoag Family Trust U/A Dtd 8/2/94
Common Stock^F2,F14	Sep 5, 2017	J	46,525	$0.00	A	46,525	I	Hamilton Investments Limited Partnership
Common Stock^F2,F18	Sep 5, 2017	J	64,302	$0.00	A	64,302	I	Goose Rocks Beach Partners, L.P.
Common Stock^F2,F16	Sep 5, 2017	J	56,832	$0.00	A	56,832	I	Reynolds Family Trust
Common Stock^F2,F20	Sep 5, 2017	J	34,060	$0.00	A	34,060	I	Drew Family Trust dated 10/5/2004
Common Stock^F2,F22	Sep 5, 2017	J	20,850	$0.00	A	20,850	I	Ten 271 Partners B
Common Stock^F2,F24	Sep 5, 2017	J	54,909	$0.00	A	54,909	I	Robert W. Trudeau
Common Stock^F2,F26	Sep 5, 2017	J	21,077	$0.00	A	21,077	I	Marshall Carroll 2000 Trust
Common Stock^F2,F28	Sep 5, 2017	J	266	$0.00	A	266	I	Marshall Partners
Common Stock^F29,F2,F9	Sep 6, 2017	S	1,300	$41.72	D	2,689	I	Technology Crossover Management VII, L.P.
Common Stock^F30,F2,F9	Sep 6, 2017	S	2,689	$42.65	D	0	I	Technology Crossover Management VII, L.P.
Common Stock^F31,F2,F24	Sep 6, 2017	S	54,909	$44.0427	D	0	I	Robert W. Trudeau

Table II — derivative securities

No Table II lines on this filing.

Explanation of responses

F1In kind pro-rata distribution by TCV VII, L.P. ("TCV VII") to its partners, without consideration.
F10In kind pro-rata distribution by TCM VII to its partners, without consideration.
F11Acquisition by the Hoag Family Trust U/A Dtd 8/2/94 pursuant to an in kind pro-rata distribution by TCM VII and TCV MF to each of their partners, without consideration.
F12Jay C. Hoag is the Trustee of the Hoag Family Trust U/A Dtd 8/2/94. Mr. Hoag disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.
F13Acquisition by the Hamilton Investments Limited Partnership pursuant to an in kind pro-rata distribution by TCM VII and TCV MF to each of their partners, without consideration.
F14Jay C. Hoag is the General Partner of Hamilton Investments Limited Partnership. Mr. Hoag disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.
F15Acquisition by the Reynolds Family Trust pursuant to an in kind pro-rata distribution by TCM VII and TCV MF to each of their partners, without consideration.
F16Jon Q. Reynolds is the Trustee of the Reynolds Family Trust. Mr. Reynolds disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.
F17Acquisition by Goose Rocks Beach Partners, L.P. pursuant to an in kind pro-rata distribution by TCM VII and TCV MF to each of their partners, without consideration.
F18Richard H. Kimball is the General Partner of Goose Rocks Beach Partners, L.P. Mr. Kimball disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.
F19Acquisition by the Drew Family Trust dated 10/5/2004 pursuant to an in kind pro-rata distribution by TCM VII and TCV MF to each of their partners, without consideration.
F2This Form 4 is filed by more than one Reporting Person and is a joint filing with the Form 4 filed by Timothy P. McAdam, John C. Rosenberg and David L. Yuan on September 6, 2017.
F20John L. Drew is the Trustee of the Drew Family Trust dated 10/5/2004. Mr. Drew disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.
F21Acquisition by Ten 271 Partners B pursuant to an in kind pro-rata distribution by TCM VII and TCV MF to each of their partners, without consideration.
F22John L. Drew is the General Partner of Ten 271 Partners B. Mr. Drew disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.
F23Acquisition by Robert W. Trudeau pursuant to an in kind pro-rata distribution by TCM VII and TCV MF to each of their partners, without consideration.
F24Shares held directly by Robert W. Trudeau.
F25Acquisition by the Marshall Carroll 2000 Trust pursuant to an in kind pro-rata distribution by TCM VII and TCV MF to each of their partners, without consideration.
F26Christopher P. Marshall is the Trustee of the Marshall Carroll 2000 Trust. Mr. Marshall disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.
F27Acquisition by Marshall Partners pursuant to an in kind pro-rata distribution by TCV MF to its partners, without consideration.
F28Christopher P. Marshall is the General Partner of Marshall Partners. Mr. Marshall disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.
F29This number represents a weighted average sales price. The shares were sold at prices ranging from $41.32 to $41.90. The Reporting Person hereby undertakes to provide upon request by the Staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each price.
F3These securities are directly held by TCV VII. Timothy P. McAdam, Jay C. Hoag, Christopher P. Marshall, Jon Q. Reynolds, Jr., Richard H. Kimball, John L. Drew, Robert W. Trudeau, John C. Rosenberg and David L. Yuan (collectively, the "TCM VII Directors") are Class A Directors of Technology Crossover Management VII, Ltd. ("Management VII") and Limited Partners of Technology Crossover Management VII, L.P. ("TCM VII"). Management VII is the General Partner of TCM VII, which is the General Partner of TCV VII, L.P. The TCM VII Directors, Management VII and TCM VII may be deemed to beneficially own the securities held by TCV VII, L.P., but each of the TCM VII Directors, Management VII and TCM VII disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein.
F30This number represents a weighted average sales price. The shares were sold at prices ranging from $42.24 to $43.04. The Reporting Person hereby undertakes to provide upon request by the Staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each price.
F31This number represents a weighted average sales price. The shares were sold at prices ranging from $44.00 to $44.165. The Reporting Person hereby undertakes to provide upon request by the Staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each price.
F4In kind pro-rata distribution by TCV VII (A), L.P. ("TCV VII (A)") to its partners, without consideration.
F5These securities are directly held by TCV VII (A). The TCM VII Directors are Class A Directors of Management VII and Limited Partners of TCM VII. Management VII is the General Partner of TCM VII, which is the General Partner of TCV VII (A). The TCM VII Directors, Management VII and TCM VII may be deemed to beneficially own the securities held by TCV VII (A), but each of the TCM VII Directors, Management VII and TCM VII disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein.
F6In kind pro-rata distribution by TCV Member Fund, L.P. ("TCV MF") to its partners, without consideration.
F7These securities are directly held by TCV MF. The TCM VII Directors are Class A Directors of Management VII, which is a General Partner of TCV MF, and Limited Partners of TCV MF. The TCM VII Directors and Management VII may be deemed to beneficially own the securities held by TCV MF, but the TCM VII Directors and Management VII each disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein.
F8Acquisition by TCM VII pursuant to an in kind pro-rata distribution by TCV VII and TCV VII (A) to each of their partners, without consideration.
F9These securities are directly held by TCM VII. The TCM VII Directors are Class A Directors of Management VII, which is the General Partner of TCM VII and Limited Partners of TCM VII. The TCM VII Directors and Management VII may be deemed to beneficially own the securities held by TCM VII, but the TCM VII Directors and Management VII each disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein.